Saturday 17 October 2026
Export CSCIF’s income statement to Excel — free account
COSCIENS Biopharma Inc.
CSCIF Healthcare Biotechnology
COSCIENS Biopharma Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.5 million, down 21.8% from fiscal 2024. In the quarter to June 2026, revenue grew 30.0%, EPS grew 92.6% and free cash flow grew 113.3%, each against the same quarter a year earlier.
6.49
0.24
+3.84%
Follow CSCIF
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.36 | 0.26 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.27 | 0.13 | 0.29 | 0.30 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
4.00 | (0.49) | (1.48) | (3.87) | |
P/B ratio |
0.16 | 0.07 | 0.57 | 0.51 | |
Price to Tangible BV |
0.16 | 0.07 | 1.07 | 0.80 | |
EV/Sales |
(0.33) | (0.49) | (0.68) | (0.69) | |
EV/EBITDA |
0.58 | 0.53 | 0.55 | 0.50 | |
EV/Operating CF |
0.77 | 0.45 | 0.61 | 0.59 | |
EV/FCF |
0.93 | 0.48 | 0.60 | 0.56 | |
Quick Ratio |
3.41 | 4.15 | 2.37 | 2.54 | |
Current Ratio |
4.33 | 5.57 | 3.18 | 3.47 | |
Net Debt/EBITDA |
(6.95) | 12.87 | 2.22 | 4.19 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.38 | 0.32 | 0.27 | 0.25 | |
Operating CF/Net income |
(2.97) | (0.20) | 0.67 | 0.37 | |
Capex/Depreciation |
0.00 | 0.02 | 0.67 | 0.01 | |
Interest Coverage |
8.27 | (15.87) | (76.06) | (54.02) | |
Research and Development Expense of Revenue |
4.20% | 9.32% | 67.57% | 35.54% | |
Selling, General and Administrative Expense of Revenue |
37.64% | 71.35% | 145.86% | 141.67% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.05% | 3.98% | (1.42%) | |
Graham Net Nets |
2.37 | 5.50 | (2.80) | (1.89) | |
Graham Number |
44.79 | 35.97 | 0.00 | 0.00 | |
Earnings Yield |
274.70% | 385.32% | (476.26%) | (574.55%) | |
Free Cash Flow Yield |
(128.89%) | (766.41%) | (391.38%) | (402.83%) | |
Revenue per Share |
3.00 | 1.80 | 2.10 | 1.40 | |
Operating CF per Share |
0.57 | (2.08) | (1.39) | (0.64) | |
Capex per Share |
0.00 | 0.01 | 0.18 | 0.00 | |
Free Cash Flow per Share |
0.57 | (2.07) | (1.21) | (0.63) | |
Cash per Share |
5.04 | 4.78 | 6.93 | 8.05 | |
Shareholders Equity per Share |
14.17 | 14.63 | 3.64 | 4.80 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
14.17 | 14.63 | 3.64 | 4.80 | |
Free Cash Flow |
0.60 | (2.17) | (1.28) | (0.67) | |
Working Capital |
7.45 | 7.71 | 7.89 | 9.85 | |
Capital Expenditures |
0.00 | 0.01 | 0.19 | 0.00 | |
Net Current Asset Value |
5.69 | 5.87 | (6.09) | (4.94) | |
EV/EBIT |
0.46 | 0.46 | 0.49 | 0.48 | |
Capex to Sales |
0.00 | 0.00 | (0.09) | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
2.58 | 1.93 | 1.87 | 1.81 | |
Average Payables |
1.93 | 2.82 | 3.31 | 3.38 | |
Average Inventory |
1.39 | 1.78 | 2.00 | 2.53 | |
Average Assets |
23.20 | 24.99 | 28.25 | 33.81 | |
Average Common Equity |
10.97 | 12.73 | 8.50 | 12.55 |
Columns are period end dates